TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. ( (JP:4882) ) has issued an announcement.
Perseus Proteomics Inc. reported progress in its drug discovery pipeline, including a completed Phase I trial for PPMX-T003 targeting polycythemia vera and advancements in other cancer therapies. The company has also initiated a collaboration with the Institute of Science Tokyo to enhance antibody drug discovery using machine learning. Financially, Perseus Proteomics saw a 12.5% increase in net sales for the first quarter of FY2026, driven by significant growth in antibody research support services.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on drug discovery and development, particularly in the field of antibody-based therapies. The company is engaged in developing treatments for diseases such as polycythemia vera and solid tumors, and it also provides antibody research support and sales of antibodies and reagents.
Average Trading Volume: 429,442
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.99B
For detailed information about 4882 stock, go to TipRanks’ Stock Analysis page.